Reset filters

Search publications


Search by keyword
List by department / centre / faculty

No publications found.

 

Developing Topics

Author(s): Silva NCBS; Stein RG; Gu Y; Hsu CL; Tam RC; Salluzzi M; McCreary CR; Alkeridy WA; Lam K; MacKay AL; Kolind S; Cossette B; Griffith LE; Hogan DB; McMillan JM; Raina P; Smith EE; Liu-Ambrose T;

Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19 and has infected >700 million persons worldwide. Individuals infected with SARS-CoV-2 are at risk for cognitive decline and at higher risk of dementia compared with those diagnosed with oth ...

Article GUID: 41434542


Cerebral small vessel disease lesion segmentation methods: A systematic review

Author(s): Phelps J; Singh M; McCreary CR; Dallaire-Théroux C; Stein RG; Potvin-Jutras Z; Guan DX; Wu JD; Metz A; Smith EE;

Cerebral small vessel disease (CSVD) can manifest as brain lesions visible on magnetic resonance imaging, including white matter hyperintensities (WMH), cerebral microbleeds (CMB), perivascular spaces (PVS), lacunes, and recent small subcortical infarcts (RSSI). Detection and segmentation of thes ...

Article GUID: 41080650


Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139


Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.

Author(s): Pieruccini-Faria F, Black SE, Masellis M, Smith EE, Almeida QJ, Li KZH, Bherer L, Camicioli R, Montero-Odasso M

INTRODUCTION: Gait impairment is common in neurodegenerative disorders. Specifically, gait variability-the stride-to-stride fluctuations in distance and time-has been associated with neurodegeneration and cognitive impairment. However, quantitative comparisons of gait impairments across the cogni ...

Article GUID: 33590967


Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Article GUID: 32725777


The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.

Author(s): Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, ...

Can J Neurol Sci. 2019 Jul 16;:1-13 Authors: Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Ph ...

Article GUID: 31309917


-   Page 1 / 1   -